Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Nove Mesto – page 27

368 clinical trials in Nove Mesto, Slovakia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Nove Mesto at a glance
368
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

368 trials in Nove Mesto

Open in trial search

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5462
  • Sponsor:AstraZeneca AB

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:SlovakiaSlovakia
  • Participants:0–17 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Nove Mesto

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Nove Mesto includes research in cardiovascular diseases, with a focus on atrial fibrillation and stable angina pectoris. These studies are designed to assess new treatment options and confirm whether emerging therapies can better prevent complications or relieve symptoms.

  • Prevention of cardioembolic events in atrial fibrillation
  • Evaluation of anti-anginal effects in stable angina pectoris
  • Testing treatment effectiveness for ongoing heart-related conditions

Overall, this area reflects active work aimed at improving both protection from serious cardiovascular events and day-to-day symptom control.

02 Digestive System and Liver Disorders

Another important research focus is digestive system diseases, especially studies involving hepatic impairment and moderate or severe hepatic impairment. These trials look at how liver problems may affect the safety and behavior of investigational therapies, helping define whether treatments can be used more effectively in people with liver disease.

  • Study of liver-related effects on treatment use
  • Research involving hepatic impairment and liver problems
  • Assessment of safety and tolerability in patients with compromised liver function

This area supports safer prescribing decisions and better understanding of how new therapies perform in patients with liver conditions.

03 Nutritional and Metabolic Diseases

Trials in nutritional and metabolic diseases are centered on hypertriglyceridemia and severe hypertriglyceridemia, reflecting a clear effort to improve management of abnormal lipid levels. The research is mainly aimed at testing whether new therapies can lower triglycerides and support better metabolic health.

  • Reduction of fasting serum triglyceride levels
  • Studies in hypertriglyceridemia and severe hypertriglyceridemia
  • Evaluation of treatment effectiveness for lipid-related disorders

These studies are relevant for patients at risk of complications linked to elevated triglycerides and broader metabolic imbalance.

04 Unspecified Therapeutic Area

Some studies in the city span broader or not fully specified categories, but they still contribute to a diverse clinical research environment. The overall pattern suggests work across multiple medical fields, with a strong emphasis on evaluating new therapies, confirming benefits, and improving how existing conditions are managed.

  • Broad clinical research across multiple disease areas
  • Testing the value of emerging treatment approaches
  • Supporting better disease management through clinical evaluation

With several recruiting sites active, the local trial landscape in Slovakia remains focused on practical questions that matter for patient care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.